The United States Supreme Court on Monday brought a definitive end to a high-stakes legal battle involving Eli Lilly and Co., declining to review a lower court’s decision that upheld a $183 million judgment against the pharmaceutical giant. The case, which centered on allegations that the company intentionally underpaid Medicaid drug rebates, has been closely watched by both the healthcare industry and constitutional scholars due to Eli Lilly’s aggressive challenge to the fundamental legality of the False Claims Act’s "qui tam" provisions. By denying certiorari, the nation’s highest court leaves intact a significant financial penalty and avoids, for now, a potentially transformative ruling on the executive branch’s authority over private litigation filed on behalf of the government.
The core of the dispute originated with a whistleblower lawsuit filed under the False Claims Act (FCA), a Civil War-era statute that allows private individuals, known as "relators," to sue entities that defraud federal programs. In this instance, the whistleblower alleged that Eli Lilly systematically manipulated its reporting of drug prices to the Medicaid program, leading to a massive shortfall in the rebates the company was legally required to pay. The Supreme Court’s refusal to hear the case solidifies a victory for the whistleblower and the federal government, while signaling that the current structure of the FCA remains robust despite growing conservative skepticism regarding its constitutional foundations.
The Genesis of the Litigation: Medicaid Rebate Underpayments
The legal saga began more than a decade ago when Ronald J. Streck, a pharmacist and attorney with expertise in drug pricing, filed a qui tam action against Eli Lilly. Streck alleged that between 2005 and 2016, the pharmaceutical manufacturer failed to properly account for "price appreciation credits" in its calculations of the Average Manufacturer Price (AMP) for several of its flagship products.
Under the Medicaid Drug Rebate Program, pharmaceutical companies are required to provide rebates to state Medicaid programs to ensure the government receives the best possible price for medications. The amount of these rebates is largely determined by the AMP. Streck’s lawsuit contended that when Eli Lilly increased the wholesale prices of its drugs, it collected "price appreciation credits" from wholesalers who held existing inventory. By failing to include these credits in its AMP reporting, Eli Lilly effectively lowered the rebate amounts it owed to the government.
The government initially declined to intervene in the case, a common occurrence in FCA litigation that allows the private relator to pursue the claim independently. After years of discovery and pre-trial motions, the case proceeded to a jury trial. In 2022, a federal jury found that Eli Lilly had acted with "reckless disregard" for the law, leading to a judgment that, when trebled under FCA mandates and combined with statutory penalties, reached the $183 million figure.
Chronology of the Legal Proceedings
The path to the Supreme Court was marked by several critical milestones that defined the scope of the controversy:
- 2014: Initial Filing – Ronald Streck filed the complaint under seal in the U.S. District Court for the Northern District of Illinois, detailing the alleged accounting discrepancies.
- 2018: Government Declination – The U.S. Department of Justice notified the court that it would not take over the prosecution of the case, allowing Streck to move forward as the primary plaintiff.
- 2022: Trial and Verdict – A district court jury returned a verdict in favor of the relator, finding that Eli Lilly’s failure to report price appreciation credits resulted in substantial losses to the Medicaid program.
- 2024: Appellate Confirmation – The Seventh Circuit Court of Appeals upheld the district court’s ruling. The appellate panel rejected Eli Lilly’s argument that the Medicaid regulations were too ambiguous to support a finding of "knowing" fraud.
- 2025: Petition for Certiorari – Eli Lilly filed its petition with the Supreme Court, pivoting from the technicalities of Medicaid accounting to a broad constitutional attack on the FCA itself.
- May 18, 2026: Denial of Review – The Supreme Court issued an order list denying the petition, effectively closing the case.
The Constitutional Challenge: Article II and the "Take Care" Clause
What elevated this case beyond a standard corporate fraud dispute was Eli Lilly’s secondary defense: a direct challenge to the constitutionality of the qui tam mechanism. The company argued that the FCA violates Article II of the Constitution, specifically the "Take Care" Clause and the Appointments Clause.
Eli Lilly’s legal team argued that by allowing a private citizen to litigate on behalf of the United States without direct supervision or the ability for the Executive Branch to dismiss the case at will, the FCA unconstitutionally strips the President of his duty to oversee the execution of federal laws. The company’s petition sought to capitalize on a 2023 dissenting opinion from Justice Clarence Thomas in United States ex rel. Polansky v. Executive Health Resources, in which Thomas suggested that the qui tam provisions might be unconstitutional.
"The relator in this case is exercising core executive power—the power to seek massive penalties in the name of the sovereign—without being an officer of the United States," Eli Lilly argued in its brief. The company contended that the lack of accountability inherent in the relator’s role creates a "shadow" Department of Justice that can pursue cases the government itself deems meritless or contrary to the public interest.
The Supreme Court’s decision to deny the petition suggests that while some justices may harbor doubts about the FCA’s structure, there is not yet a majority ready to dismantle a statute that has recovered more than $70 billion for the federal treasury since 1986.
Supporting Data and Financial Impact
The $183 million judgment represents one of the more significant FCA recoveries involving Medicaid rebate calculations in recent years. To put this figure in perspective, the Department of Justice reported that in the fiscal year 2023 alone, it obtained more than $2.68 billion in settlements and judgments from civil cases involving fraud and false claims against the government. Of that total, over $1.8 billion related to the healthcare industry, including drug manufacturers, hospitals, and pharmacies.
Data from the Centers for Medicare & Medicaid Services (CMS) indicates that the Medicaid Drug Rebate Program is a vital component of state budgets. In 2023, the program generated approximately $42 billion in rebates that were shared between the federal government and the states. Legal experts suggest that if Eli Lilly’s accounting methods had been permitted to stand, it could have set a precedent allowing other manufacturers to shield billions of dollars in price increases from the rebate formula.
The breakdown of the $183 million award includes:
- Actual Damages: Approximately $61 million in estimated underpaid rebates.
- Treble Damages: Under the FCA, actual damages are multiplied by three to deter future fraud, totaling $183 million.
- Statutory Penalties: Additional fines ranging from roughly $13,000 to $27,000 per false claim filed.
Official Responses and Industry Reaction
While Eli Lilly expressed disappointment in the Court’s decision, the company maintained that its actions were based on a "reasonable interpretation" of complex and often contradictory federal regulations.
"We continue to believe that the pharmaceutical industry requires clear, consistent guidance from regulators," a spokesperson for Eli Lilly said in a brief statement following the announcement. "The use of the False Claims Act to punish companies for differing interpretations of ambiguous rules creates an environment of uncertainty that ultimately harms innovation."
Conversely, advocates for the False Claims Act hailed the denial of certiorari as a victory for taxpayers. "The Supreme Court has once again signaled that the False Claims Act is a constitutional and essential tool for protecting the public purse," said a representative from Taxpayers Against Fraud, a non-profit whistleblower advocacy group. "This decision ensures that whistleblowers can continue to hold powerful corporations accountable when the government lacks the resources or the political will to do so."
Legal analysts noted that the Department of Justice had urged the Court to deny the petition, arguing that the government maintains sufficient control over qui tam litigation through its ability to intervene, move to dismiss, or settle cases over a relator’s objections.
Broader Implications for the Pharmaceutical Industry
The Supreme Court’s refusal to intervene has immediate and long-term implications for the pharmaceutical sector. First, it reinforces the "scienter" (knowledge) standard established in the 2023 case United States ex rel. Schutte v. SuperValu Inc. In that case, the Court ruled that a defendant’s subjective belief about the lawfulness of their actions is what matters, rather than whether a "reasonable person" could have found the regulations ambiguous. By leaving the Eli Lilly judgment in place, the Court affirms that companies cannot hide behind regulatory complexity if evidence suggests they knew, or recklessly disregarded, the fact that their claims were false.
Furthermore, the survival of the qui tam provision means that pharmaceutical companies must remain vigilant regarding their internal compliance and reporting mechanisms. The threat of a whistleblower—often an internal employee or an industry expert with access to proprietary data—remains the most significant driver of FCA enforcement.
The industry is also likely to see an increase in "price appreciation credit" audits. With the legal precedent now firmly established in the Seventh Circuit and left undisturbed by the Supreme Court, other manufacturers who utilized similar accounting practices may find themselves targets of both whistleblower suits and government investigations.
The Future of the False Claims Act
Despite this setback for Eli Lilly, the constitutional debate surrounding the False Claims Act is unlikely to vanish. Legal scholars point out that several other cases currently moving through lower courts also challenge the Appointments Clause and the Take Care Clause. If a circuit split emerges—where one appellate court finds the qui tam provisions unconstitutional while others uphold them—the Supreme Court may be forced to take up the issue in a future term.
For now, the $183 million judgment stands as a stark reminder of the financial risks associated with federal program non-compliance. For Eli Lilly, the denial marks the end of a twelve-year litigation cycle. For the broader legal community, it serves as a confirmation that the False Claims Act remains the "primary weapon" in the government’s arsenal against healthcare fraud, shielded from constitutional challenges for at least another chapter in American legal history.
